Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design

Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design

ObjectiveCeftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) Gram-negative (G−) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas aeruginosa. Growing evidence indicates that critically ill intens...

Full description

Saved in:
Bibliographic Details
Main Authors: Mirna Momčilović, Ivan Šitum, Ante Erceg, Marko Siroglavić, Mila Lovrić, Laura Nižić Nodilo, Anita Hafner, Jasmina Lovrić, Petra Turčić, Dora Fabijanović, Ana Marinić, Vanja Nedeljković, Marijan Pašalić, Luka Perčin, Dubravka Šipuš, Davor Miličić, Daniel Lovrić
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pharmacology
Subjects:
ceftazidime/avibactam
continuous infusion
critically ill
ICU
Klebsiella pneumoniae OXA-48
NCT06811727
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1618987/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1618987/full

Similar Items